Drug therapy is a powerful tool for improving neonatal outcome. Despite this, neonatologists still routinely prescribe off-label compounds developed for adults and extrapolate doses from those used for children or adults. Knowledge integration through pharmacokinetic modeling is a method that could improve the current situation. Such predictive models may convert neonatal pharmacotherapy from explorative to confirmatory. This can be illustrated by research projects related to the prediction of neonatal renal clearance and neonatal glucuronidation. This type of model will also improve the current knowledge of neonatal (patho)physiology. In the meanwhile, the fields of clinical pharmacology (e.g. pharmacokinetic/pharmacodynamic modeling and pharmacogenetics) and neonatology (e.g. whole-body cooling and the lower limit of viability) have both matured, resulting in new research topics. However, in order for the modeling and the newly emerging topics to become effective tools, they need to be tailored to the specific characteristics of neonates. Consequently, the field of neonatal pharmacotherapy needs dedicated neonatologists who continue to raise the awareness that off-label practices, eminence-based dosing regimens and the absence of neonatal drug formulations all reflect suboptimal care.

Keywords:
Neonatal pharmacotherapy, Off-label compounds, Suboptimal care
1.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE: Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-1167.
2.
Allegaert K, Verbesselt R, Naulaers G, van den Anker JN, Rayyan M, Debeer A, de Hoon J: Developmental pharmacology: neonates are not just small adults. Acta Clin Belg 2008;63:16-24.
3.
De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA: The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2011;67(suppl 1):5-16.
4.
Smits A, Kulo A, de Hoon JN, Allegaert K: Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations. Curr Pharm Des 2012;18:3119-3146.
5.
Barrett JS, Della Casa Alberighi O, Läer S, Meibohm B: Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther 2012;92:40-49.
6.
Strougo A, Eising T, Yassen A, Willmann S, Danhof M, Freijer J: First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J Pharmacokinet Pharmacodyn 2012;39:195-203.
7.
Knibbe CA, Danhof M: Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm 2011;415:9-14.
8.
De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, Danhof M, Knibbe CA: Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet 2012;51:105-117.
9.
De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, Danhof M, Knibbe CA: A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res 2014;31:754-767.
10.
Krekels EH, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, Mirochnick M, Knibbe CA: From pediatric covariate model to semiphysiological function for maturation. Part I. Extrapolation of a covariate model from morphine to zidovudine. CPT Pharmacometrics Syst Pharmacol 2012;1:e9.
11.
Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, Holford N, Kimura T, Lo YL, Peris JE, Thomson A, van den Anker JN, Fakhoury M, Jacqz-Aigrain E: External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol 2013;75:1068-1080.
12.
Allegaert K, Rochette A, Veyckemans F: Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Paediatr Anaesth 2011;21:266-273.
13.
De Cock RF, Allegaert K, Vanhaesebrouck S, de Hoon J, Verbesselt R, Danhof M, Knibbe CA: Low but inducible contribution of renal elimination to clearance of propylene glycol in preterm and term neonates. Ther Drug Monit 2013, Epub ahead of print.
14.
Salem F, Johnson TN, Barter ZE, Leeder JS, Rostami-Hodjegan A: Age-related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Pharmacol 2013;53:857-865.
15.
Leeder JS, Kearns GL, Spielberg SP, van den Anker J: Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 2010;50:1377-1387.
16.
Leeder JS, Kearns G: Interpreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target. Clin Pharm Ther 2012;92:434-436.
17.
Allegaert K, van den Anker JN, de Hoon JN, van Schaik RH, Debeer A, Tibboel D, Naulaers G, Anderson BJ: Covariates of tramadol disposition in the first months of life. Br J Anaesth 2008;100:525-532.
18.
Zhu R, Kiser JJ, Seifart HI, Werely CJ, Mitchell CD, D'Argenio DZ, Fletcher CV: The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol 2012;52:511-519.
19.
Durrmeyer X, Hovhannisyan S, Médard Y, Jacqz-Aigrain E, Decobert F, Barre J, Alberti C, Aujard Y, Danan C, Baud O: Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants? PLoS One 2010;5:e12329.
20.
Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, Terrin N, Huggins GS, Aranda JV, Davis JM: Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013;309:1821-1827.
21.
Sistonen J, Madadi P, Ross CJ, Yazdanpanah M, Lee JW, Landsmeer ML, Nauta M, Carleton BC, Koren G, Hayden MR: Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther 2012;91:692-699.
22.
Wildschut ED, van Saet A, Pokorna P, Ahsman MJ, van den Anker JN, Tibboel D: The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children. Pediatr Clin North Am 2012;59:1183-1204.
23.
Van den Broek MP, Groenendaal F, Toet MC, van Straaten HL, van Hasselt JG, Huitema AD, de Vries LS, Egberts AC, Rademaker CM: Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach. Clin Pharmacokinet 2012;51:671-679.
24.
Van den Broek MP, Rademaker CM, van Straaten HL, Huitema AD, Toet MC, de Vries LS, Egberts AC, Groenendaal F: Anticonvulsant treatment of asphyxiated newborns under hypothermia with lidocaine: efficacy, safety and dosing. Arch Dis Child Fetal Neonatal Ed 2013;98:F341-F345.
25.
Liu X, Borooah M, Stone J, Chakkarapani E, Thoresen M: Serum gentamicin concentrations in encephalopathic infants are not affected by therapeutic hypothermia. Pediatrics 2009;124:310-315.
26.
Van Wassenaer AG, Kok JH: Trials with thyroid hormone in preterm infants: clinical and neurodevelopmental effects. Semin Perinatol 2008;32:426-430.
27.
Du W, Tutag Lehr V, Lieh-Lai M, Koo W, Ward RM, Rieder MJ, van den Anker JN, Reeves JH, Mathew M, Lulic-Botica M, Aranda JV: An algorithm to detect adverse drug reactions in the neonatal intensive care unit: a new approach. J Clin Pharmacol 2013;53:87-95.
28.
Shinwell ES: Optimization of airway medications in the infant. Neonatology 2013;103:331-334.
29.
Stenson BJ: Oxygen targets for preterm infants. Neonatology 2013;103:341-345.
30.
Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Vento M, Halliday HL: European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants - 2013 update. Neonatology 2013;103:353-368.
31.
Teune MJ, van Wassenaer AG, Malin GL, Asztalos E, Alfirevic Z, Mol BW, Opmeer BC: Long-term child follow-up after large obstetric randomised controlled trials for the evaluation of perinatal interventions: a systematic review of the literature. BJOG 2013;120:15-22.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.